Failure n(%) | p-value | |
---|---|---|
Sex | 0.97 | |
Male | 8/92 (8.7) | |
Female | 4/48 (8.3) | |
Type of prosthetic material | 0.001 | |
Total hip replacement | 2/38 (5.3) | |
Total knee replacement | 5/13 (38.5) | |
Total ankle replacement | 0/2 (0) | |
All prosthesis | 7/53 (13.2) | |
Intramedullary nailing | 2/16 (12.5) | |
Plate/screw/pin | 3/71 (4.2) | |
Type of surgery | 0.33 | |
Intra-articular washa | 6 (11.3) | |
One-stage revision | 2 (15.4) | |
Two-stage revision | 3 (14.3) | |
Material removal | 1 (2.5) | |
Mobile inserts change | 0 (0) | |
Type of infection | 0.01 | |
Type I | 0/5(0) | |
Type II | 2/58 (3.5) | |
Type III | 2/51 (4) | |
Type IV | 6/28 (21.5) | |
Infection by inoculation | 9/115 (7.8) | |
S. aureus susceptibility | 0.01 | |
Methicillin susceptible | 6/113 (5.3) | |
Methicillin resistant | 6/27 (22.2) | |
Intravenous antibiotic therapy | 0.15 | |
Empiric therapy following guidelines | 6/104 (5.7) | |
Empiric therapy not following guidelines | 6/26 (16.6) | |
Duration of intravenous antibiotic therapy | 0.47 | |
≤ 5 days | 9/119 (7.5) | |
> 5 days | 3/21 (14.2) | |
Oral antibiotic therapy | 0.42 | |
Rifampicin + Ofloxacin | 6/88 (6.8) | |
Rifampicin + Cotrimoxazole | 2/21 (4.8) | |
Rifampicin + another antibiotic | 2/8 (25.0) | |
Combination without rifampicin | 3/22 (13.6) | |
Chronic comorbidities | 0.17 | |
Diabetes mellitus | 2/21 (9.5) | |
Obesity | 4/24 (16.7) | |
Chronic renal failure | 1/12 (8.3) | |
Cancer, history of radiotherapy, immunosuppressive therapy | 0/25 (0) |